0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > APRIL

APRIL

Brief Information

Name:Tumor necrosis factor ligand superfamily member 13
Target Synonym:TNF- and APOL-related leukocyte expressed ligand 2,TNFSF13,TNF-related death ligand 1,ZTNF2,TALL-2,APRIL,Tumor necrosis factor ligand superfamily member 13,TNF Superfamily Member 13,Tumor Necrosis Factor (Ligand) Superfamily, Member 13,TRDL-1,TALL2,Tumor
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

APL-H52D1-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human APRIL, His,Flag Tag, active trimer (Cat. No. APL-H52D1) on HIS1K Biosensor, can bind Human BCMA, Fc Tag (Cat. No. BC7-H5254) with an affinity constant of 1.88 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

APL-H52D1-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human APRIL, His,Flag Tag, active trimer (Cat. No. APL-H52D1) on HIS1K Biosensor, can bind Human TACI/TNFRSF13B, Fc Tag (Cat. No. TAI-H5256) with an affinity constant of 75 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

APRIL,TNFSF13,TALL-2,TRDL-1,CD256,TALL2,ZTNF2

Background

APRIL(a proliferation-inducing ligand) is also known as Tumor necrosis factor ligand superfamily member 13, TALL-2, TRDL-1, CD256, TNFFSF 13, cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. APRIL is a cytokine of the tumor necrosis factor family associated mainly with hematologic malignancies. The closely related TNF family ligands B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) serve in the generation and maintenance of mature B-lymphocytes. Both BAFF and APRIL assemble as homotrimers that bind and activate several receptors that they partially share. BAFF-APRIL heteromers of different stoichiometries have distinct receptor-binding properties and activities. In addition, expression of APRIL was regulated by miR-145 in GC cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Telitacicept RCT-18; RC-18; RCT18; RC18 Approved Rc Biotechnologies Ltd 泰爱 Mainland China Lupus Erythematosus, Systemic RemeGen Co Ltd 2021-03-09 Multiple Sclerosis, Relapsing-Remitting; Myasthenia Gravis; Glomerulonephritis, IGA; Arthritis, Rheumatoid; Sjogren's Syndrome; Multiple Sclerosis; Lupus Erythematosus, Systemic; Neuromyelitis Optica Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VIS-649 VIS-649 Phase 2 Clinical Visterra Glomerulonephritis, IGA; Glomerulonephritis Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) Clinical Huazhong University Of Science And Technology Multiple Myeloma Details
BCMAxCD3 bispecific antibody (Regeneron) REGN-5458 Phase 2 Clinical Regeneron Pharmaceuticals Inc Multiple Myeloma Details
APRIL CAR-T Cell therapy (Yake Biotechnology) Phase 1 Clinical Multiple Myeloma Details
BION-1301 BION-1301 Phase 2 Clinical Aduro Biotech Glomerulonephritis, IGA; Multiple Myeloma Details
bb-21217 bb-21217 Phase 1 Clinical Bluebird Bio Multiple Myeloma Details
Atacicept TACI-Ig Phase 3 Clinical Zymogenetics Glomerulonephritis, IGA; Arthritis, Rheumatoid; Optic Neuritis; Multiple Sclerosis; Lupus Nephritis; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
RO-7297089 RO-7297089; AFM-26; RG-6296 Phase 1 Clinical Genentech Inc Multiple Myeloma Details

This web search service is supported by Google Inc.

totop